Ticagrelor

Description:

API nomen est scriptor indication specification US DMF  EU DMF  BOLETUS
Ticagrelor anticoagulant In Domus, 28984  

Product Detail

Product Tags

FRUCTUS SINGULA

Maecenas vitae

Ticagrelor autem novam mortem occupavi ad P2Y12 receptor [I].

Ticagrelor relata ad prothrombotic inhibere platelet ab effectis ad ADP in P2Y12 receptor. Inhibitionis de platelet aggregatio Ticagrelor completum est ostensum est quod ex vivo. Praeterea Ticagrelor est dependens suggesserant, inhibitionis de platelet aggregatio, in homini qui iamiam terminantur. Praeter haec, etiam Ticagrelor demonstratum est viva voce, active operata est, reversibly binding alterius. Secus alii inhibitors, nuntiavit Ticagrelor etiam ad inhibere P2Y12 receptor sine metabolismi mutatio. Praeter id, quod Ticagrelor thienopyridine primo agente et maxime anti-platelet metabolized per CYP3A4 et CYP2C19 [I] [II].

Re:
[I] Zhou D1, Jeps TB, Grimm Magis Zephyrus quam Auster. Herpesvirus hominis potential medicamento-medicamento interactiones ticagrelor autem iudicium: cytochrome P450 Phenotyping reactionem, inhibitionis, inductionem et differentiali equilibrium. Metab medicamento Dispos. Apr MMXI, XXXIX (IV), 703-10.
[II] Li Y1, Landqvist C, quam Auster Grimm. Ticagrelor dispositio et metabolismi, novus P2Y12 receptor, in mures, mures; et: quas. Metab medicamento Dispos. Sep MMXI, XXXIX (IX): 1555-67. doi: 10,1124 / dmd.111.039669. Iun Epub MMXI XIII.

Description

Ticagrelor (AZD6140) est, convertitur enim curatio de platelet aggregatio oris P2Y12 receptor.

In vitro

Ticagrelor promovet in maius praeceptum V adenosine'-diphosphate (ADP)-+ release Ca2 adductus est in platelets nobis tibus aliisque P2Y12R antagonistis suscipiunt. Hoc autem additional effectum ticagrelor ultra P2Y12R immo partim ex eadem etiam ticagrelor inhibentes Magistro equilibrative nucleoside transporter I (ENT1) in platelets, ducens ad cumulum extracellular adenosine et activation de Gs, adenosine coupled A2A receptorum [I]. B16 F10 cellulis, platelets et sic exhibent coeperunt minui commercium tractata, a ticagrelor habebat mures aureos comparari SAL-tractata [II].

In B16-F10 melanoma intravenous et metastasis intrasplenic exempla monstrabit, et quinque mures aureos tractata et rubore laudabunt orci ticagrelor (X mg / kg) exhibet notatum reductiones in pulmone (LXXXIV%) et iecur (LXXXVI%) metastases. Ceterum ticagrelor curatio improves salvos SAL-tractata bestiae comparari. 4T1 pectus cancer similis effectus accipitur in exemplum: pulmonibus ad reductiones (LV%) et medullae ossium (LXXXVII%) metastases ticagrelor sequenti curatio [II]. Una administratio ab oris ticagrelor (1-10 mg / kg) potionis causa-related inhibitory effectum in platelet aggregatio. Ticagrelor ad summum dose (X mg / kg) significantly inhibits platelet aggregatio I h ​​post dosing ad apicem, et praeceptum est circa IV post h dosing.

storage

4DieC. Ab luce Ethiopia NITROGENIUM

* Et solvendo: -80DieC, VI menses; -20DieC, mense I (protegat de lumine pleno per nitrogen)

eget compages

Ticagrelor

CERTIFICATE

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

QUALITY MANAGEMENT

Quality management1

rogationem 18 Aestimatio qualis Constantia quae probatus projects 4, et 6 projects sub consilio.

Quality management2

Qualis international venditio procuratio ratio provecta iam posuit fundamentum.

Quality management3

Qualis vigilantia fugit per totum vitae cursum ad curare quale productum est ac medicinales effectus. 

Quality management4

Demandis regulatory Negotiis professio bigas species sustinet et adnotatione durante application.

PROLATIO MAGISTERIUM

cpf5
cpf6

Korea Countec packaging linea Bottled

cpf7
cpf8

Taiwan CVC packaging linea Bottled

cpf9
cpf10

CAM packaging linea Italia Board

cpf11

Fette artans German Apparatus

cpf12

Iaponia Viswill Traba Detector

cpf14-1

Des Control Room

SOCIUS

internationalis cooperante
International cooperation
domesticis cooperante
Domestic cooperation

  • priorem:
  • Deinde:

  • Dimitte nobis scribere Read more